APTA-16

N/A

Report date: 2022/02/11 17:34:38
NME

Base Information

Drug NameAPTA-16
Drug Alias NameAPTA-16SJP1604
ClassificationSmall molecules
Mechanisms of ActionNucleolin inhibitorsHistone methyltransferases inhibitors
TargetsNucleolin
Therapy Area/IndicationsMyelodysplastic SyndromesLiver NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAptabio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAptabio Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLiver NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A